Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.25    0.00 (0.00%)
Bid:
6.00
Ask:
6.50
Spread: 0.50 (8.333%)
Market Cap: £6.46m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Half-yearly Report

30 Apr 2012 12:00

CERES MEDIA INTERNATIONAL PLC ("Ceres" or the "Company" or the "Group") Chairman's Statement Ceres is a supplier of environmentally friendly and sustainable materials forthe 'Out of Home' and 'In-store' print industry and has made progress indeveloping suitable materials and expanding its distribution chains for thedelivery of these into the United Kingdom; USA and European markets during

thepast six months.

The Board presents its results for the 6 months to 31 January 2012.

As notified in recent announcements the Company's trading has been belowdirectors' expectations. Revenues for the 6 months to January 2012 were £53,000. Performance has been impacted by the poor general economic conditionsand specific structural issues impacting the print material distributionsector, especially in the United Kingdom. The directors have reacted to thesechanges by refocusing the Company's sales strategy by directly targetingpotential end users of the product, simplifying the distribution process andoptimising price competitiveness. The Company has started to see positive results from this strategy, both interms of revenues as well as potential pipeline opportunities. The Company isin discussions and advanced product testing with a number of premium brandedentities as well as directly with 'Out of Home' media organisations with theintention to supply product directly to these users. Additionally, the Companyhas recently received its first orders for Nature Netting, the Company's newevent screening product designed specifically to support high profile eventstaking place in the UK during the summer. In relation to the sales of Chorus and Gossyp ranges, these remain below theboard's expectations, although there have been recent indications ofimprovements in off-take for Chorus in the USA and Europe. After extensivetesting Chorus and Gossyp were approved in March 2012 by Hewlett Packard ("HP")for use on its digital print machines - this will build significant confidencewith printers who use HP's printers as well as provide manufacturer approvedsettings for optimal use on both products. Awareness of the NatureWovenTMrange of products continues to increase and the Company is pleased to have beennominated as a finalist at the recent Sustainable Business Council of LosAngeles Awards. TierraFilmTM window cling product was launched in January 2012, however,technical issues surrounding the physical fixing process have led to slowerthan anticipated off-take - the directors anticipate that a newly formulatedand improved TierraFilmTM window cling product will be available in the UKmarket in June 2012. TierraFilmTM 'Backlit 100 product has tested well and itis anticipated will be listed by two major 'Out of Home' media owners shortly. Working capitalIn the light of continued lower than expected sales, the directors havesignificantly reduced overhead and continue to carefully manage workingcapital. The directors are also actively managing the current stock levels tobring them more into line with current trading. The Company will need to haveaccess to further working capital in the short term to allow it to financeanticipated sales growth. The board are considering a number of options.

Board change

Norman Fetterman, who has recently celebrated his 70th birthday has today announced he has resigned as a director of the Company. The Board would like to thank Mr. Fetterman for leading the business through the AIM flotation process in 2011 and beyond.

The board is seeking to appoint an additional director to the board; a further announcement will be made in due course.

The Company has experienced tough trading conditions since admission of itsshares to AIM in September 2011, the directors albeit cautions about the futureare optimistic that the Company's products can be successfully exploited in newand developing markets. The board would like to thank shareholders for theircontinued support of the Company. Leslie Barber, Chairman said "Whilst sales during the first six months of the year were very disappointing,marketing campaigns in both US and Europe are beginning to show results with agradual turnover build so far in 2012. Market interest in our products is encouraging and we are in discussions withnumerous major parties. We are focussed on ensuring that this continuedcustomer interest is converted into orders as quickly as possible and that allour products meet the environmental requirements we have set out to satisfy.

TierraFilmBacklit has now been developed and tested with three major 'Out of Home' media owners and approvals are expected shortly. TierraFilm's image reproduction qualities above all other benefits are proving to be the over-riding USP and the key reason for advertiser interest.

The recent success of the new to market Jute based Nature Netting product hasbeen welcomed, initial orders are encouraging and we are continuing to marketthis, as well as our other product lines, aggressively, albeit within thecurrent constraints of our working capital position." Contact details:- Ceres Media International PLC Tel: 020 3178 5622Alex Dowdeswell / Leslie Barber

Nominated Adviser - Cairn Financial Advisers LLP Tel: 020 7148 7900 Jo Turner / Liam Murray

Broker - First Columbus LLP Tel: 020 3002 2070Chris Crawford / Kelly Gardiner Financial PR - De Facto Financial Tel: 020 7556 1063Mike Wort / Anna Dunphy CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOMEFor the six months ended 31 January 2012 six months Period 1 March 2011 Notes to 31 January 2012 to 31 July 2011 (unaudited) (Audited) £ £ CONTINUING OPERATIONS Revenue 2 52,832 30,054 Cost of Sales (32,563) (37,688) Administrative Expenses (472,807) (472,532) OPERATING LOSS (452,538) (480,166) Interest Income 0 250 Finance Costs (2,407) (4,859) LOSS BEFORE TAX (454,945) (484,775) Taxation 0 0 TOTAL COMPREHENSIVE (454,945) (484,775) EXPENSE FOR THE YEAR LOSS PER SHARE LOSS PER SHARE 4 0.015 0.021 BALANCE SHEETAs at 31 January 2012 At 31 January 2012 At 31 July 2011 (unaudited) (Audited) £ £ ASSETS NON-CURRENT ASSETS Goodwill 868,088 868,088 Intangible Assets 255,213 223,306 Property, plant and equipment 15,384 9,057 1,138,685 1,100,451 CURRENT ASSETS Inventories 403,975 162,663 Trade and other receivables 49,790 98,313 Cash and cash equivalents 79,970 55,911 533,735 316,887 TOTAL ASSETS 1,672,420 1,417,338 EQUITY SHAREHOLDERS' EQUITY Called up share capital 5,260,069 5,200,348 Share premium 831,887 0 Other reserves (3,444,553) (3,444,552) Retained earnings (1,330,117) (875,172) TOTAL EQUITY 1,317,286 880,624 LIABILITIES CURRENT LIABILITIES Trade and other payables 304,731 536,714

Financial liabilities: borrowings Interest bearing loans and borrowings 50,403

0 TOTAL LIABILITIES 355,134 536,714 TOTAL EQUITY AND LIABILITIES 1,672,420 1,417,338 CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITYAs at 31 January 2012 Called up Share Merger Reverse Profit and Total Share capital Premium reserve acquisition loss account Equity reserve £ £ £ £ £ £ At 1 August 2011 5,200,348 1,157,850 (4,602,402) (875,172) 880,624 Issue of Equity 59,721 831,887 891,607 Loss for the period (454,945) (454,945) At 31 January 2012 5,260,069 831,887 1,157,850 (4,602,402) (1,330,117) 1,317,286 Called up Share Merger Reverse Profit and Total Share capital Premium reserve acquisition loss account Equity reserve £ £ £ £ £ £ At 1 March 2011 150,539 419,249 (390,397) 179,391 Issue of Equity: Consideration shares 4,042,498 4,042,498 Other shares issued 272,850 272,850 Reverse acquisition reserve 734,461 (419,249) 1,157,850 (4,602,402) (3,129,340)conversion Loss for the period (484,775) (484,775) At 31 July 2012 5,200,348 1,157,850 (4,602,402) (875,172) 880,624 CONSOLIDATED STATEMENT OF CASH FLOWSFor the six months ended 31st January 2012 Six months Period to 31 January 2011 to 31 July 2011 (Audited) £ £

Cash flows from operating activities

Loss before tax (454,945) (484,775) Depreciation charges 2,405 1,304 Investment income 0 (250) Increase in inventories (241,312) (114,470)

(Increase)/decrease in trade and other receivables 48,523

50,144

Increase/(decrease) in trade and other payables (231,983)

229,629

Net cash from operating activities (877,312)

(314,418)

Cash flows from investing activities Purchase of intangible fixed assets (31,907)

(28,006)

Purchase of tangible fixed assets (6,327)

(6,921)

Acquisition of subsidiaries, net of cash 0

385,144 Finance income received 0 250

Net cash from investing activities (38,234)

350,467

Cash flows from financing activities

New loans in the year 109,005 Issue of equity net of costs 891,609 10,334 Repayment of loan (58,602) Finance interest paid (2,407)

Net cash from financing activities 939,605

10,334

Increase/(decrease) in cash and cash

equivalents 24,059 42,383

Cash and cash equivalents at the beginning

of period 55,911 13,528

Cash and cash equivalents at end of period 79,970

55,911

NOTES TO THE HALF YEARLY REPORT

1 GENERAL INFORMATION

Ceres Media International plc is a public limited company incorporated and domiciled in the United Kingdom with its shares listed on the AIM market of the London Stock Exchange.

The principal activity of the Group is the development, production and provision of 100% natural and compostable printing materials to the advertising and point of sale markets.

The Ultimate parent company of the Group is Ceres Media International plc whose principle place of business is 81 Rivington Street, London, EC2A 3AY and registered office is Acre House, 11-15 William Road, London NW1 3ER.

The interim financial statements for the period ended 31 January 2012(including the comparatives for the period ended 31 July 2011) were approved bythe Board of Directors on 30 April, 2012. Under the Security Regulations Actof the European Union ("EU"), amendments to the financial statements are notpermitted after they have been approved.The financial information set out in this interim report does not constitutestatutory accounts as defined in Section 434 of the Companies Act 2006. TheGroup's statutory financial statements for the year ended 31 July 2011,prepared under International Financial Reporting Standards ("IFRS"), have beenfiled with the Registrar of Companies. The auditor's report on those financialstatements was unqualified and did not contain statements under Sections 498(2)and 498(3) of the Companies Act 2006.The interim financial information has been prepared using the accountingpolicies set out in the Group's 2011 statutory accounts. Copies of the annualstatutory accounts and the interim report may be obtained by writing to CeresMedia International plc, 81 Rivington Street, London EC2A 3AY and can be foundon the Company's website at www.ceresmediaplc.com2 SEGMENTAL REPORTING Six months Period to 31 January 2012 to 31 July 2011 EU 36,443 16,817 Rest of the world 16,389 13,237 52,832 30,054 3 EXCEPTIONAL ITEMS

The Group incurred exceptional items of £300,281 in relation to costs incurred to list the company on AIM and the share issue during the period.

4 EARNINGS / (LOSS) PER SHARE

The calculation of earnings per share is based on the net result and ordinary shares in issue during the period as follows:

£ £ Loss for the financial period 454,945 484,775

Weighted average shares in issue in the period 30,978,591 23,373,726

Loss per share 0.015 0.021 5 SHARE CAPITALDuring the period Ceres Media International plc issued the following shares

Ordinary shares of 20p/1p each In issue at 1 August 2011 26,001,739 Issued during the period 5,972,222 In issue at 31 January 2012 31,973,961

On 26th August 2011 the company converted each Ordinary Share of 20p into one

new Ordinary Share of 1p and a Deferred Share of 19p

Date   Source Headline
31st Mar 20207:00 amRNSExclusive licence agreement for OptiBiome®
24th Mar 20207:00 amRNSExtension of territories for GoFigure®
23rd Mar 20207:00 amRNSChange of accounting year end
19th Mar 20204:42 pmRNSSecond Price Monitoring Extn
19th Mar 20204:38 pmRNSPrice Monitoring Extension
19th Mar 20202:06 pmRNSSecond Price Monitoring Extn
19th Mar 20202:01 pmRNSPrice Monitoring Extension
19th Mar 202011:05 amRNSSecond Price Monitoring Extn
19th Mar 202011:00 amRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSDistribution Agreement for SlimBiome® Medical
16th Mar 202011:56 amRNSDirector’s Dealing
12th Mar 20204:44 pmRNSSecond Price Monitoring Extn
12th Mar 20204:39 pmRNSPrice Monitoring Extension
12th Mar 20202:05 pmRNSSecond Price Monitoring Extn
12th Mar 20202:00 pmRNSPrice Monitoring Extension
12th Mar 20207:00 amRNSNew partner for LPLDL® in Bulgaria
11th Mar 20207:00 amRNSExtension of LPLDL® supply agreement with SACCO
25th Feb 20207:00 amRNSMarketing update
17th Feb 20207:06 amRNSDistributor agreement for LPLDL®
12th Feb 20207:00 amRNSExtension of LPLDL® into Dairy Products
31st Jan 20207:00 amRNSLaunch of SlimBiome® in North America
28th Jan 20207:00 amRNSExtension of term and territories for products
27th Jan 20207:00 amRNSLaunch of LPLDL® product with AlfaSigma
17th Jan 20207:00 amRNSTrading Update
8th Jan 20207:00 amRNSLPLDL® reduces high blood pressure
7th Jan 20207:00 amRNSLaunch of SlimBiome® range in Holland & Barrett
19th Dec 20197:00 amRNSSlimBiome® distribution agreement for Germany
17th Dec 20197:00 amRNSAnthem BioPharma launches two products in India
9th Dec 20197:00 amRNSDistribution agreement for CholBiome®x3
6th Dec 20197:00 amRNSGoFigure® and SlimBiome® commercial updates
5th Dec 20197:00 amRNSSlimBiome® Medical update
4th Dec 20197:00 amRNSAppointment of European Sales Leader - ProBiotix
6th Nov 201910:38 amRNSHolding(s) in Company
9th Oct 20197:00 amRNSLPLDL® Pharmaceutical GMP process validation
18th Sep 20197:00 amRNSGoFigure® agreement for Southern Africa
28th Aug 201910:00 amRNSDirector's Dealing
28th Aug 20197:00 amRNSHolding(s) in Company
28th Aug 20197:00 amRNSDirectorate Change
28th Aug 20197:00 amRNSHalf-year Report
12th Aug 20197:00 amRNSManufacturing, supply and profit sharing agreement
29th Jul 20194:03 pmRNSTransfer of certain SkinBioTherapeutics plc shares
18th Jul 20197:00 amRNSOnline distribution agreement - SlimBiome® Medical
11th Jul 20197:00 amRNSScientific and commercial update
3rd Jul 20197:00 amRNSLicense agreement for LPLDL® in Japan
1st Jul 20197:00 amRNSLPLDL® license agreement with Kappa Bioscience AS
25th Jun 20197:00 amRNSAppointment of goetzpartners securities Limited
24th Jun 20197:00 amRNSManufacturing agreement with Agropur
11th Jun 20194:55 pmRNSResult of AGM
10th Jun 20197:00 amRNSLicense agreement for CholBiome® in Vietnam
29th May 20193:17 pmRNSDirector's Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.